培美曲塞联合奥沙利铂治疗晚期非小细胞肺癌的疗效及安全性分析

目的研究培美曲塞联合奥沙利铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法NSCLC患者110例,随机分为培美曲塞联合奥沙利铂治疗组（研究组）及单纯培美曲塞治疗组（对照组）各55例,比较两种治疗方案的临床疗效及不良反应发生率。结果研究组疗效优于对照组（P〈0.05）。两组血红细胞下降、肌酐增高、呕吐、皮疹、过敏性反应的发生情况组间差异无统计学意义（P〉0.05）。研究组粒细胞下降、血小板下降、AST增高、恶心、疲乏、感觉异常的发生率均高于对照组,差异有统计学意义（P〈0.05）。结论培美曲塞联合奥沙利铂治疗晚期NSCLC的临床疗效优于单纯培美曲塞治疗,但是不良反应较多,应注意控制。

Efficacy and Safety of Pemetrexed Combined with Oxaliplatin in Treatment of Advanced Non-Small Cell Lung Cancer

Objective To study the efficacy and safety of pemetrexed combined with oxaliplatin in the treatment of advanced non-small cell lung cancer（ NSCLC）. Methods One hundred and ten NSCLC patients were randomly divided into study group treated with pemetrexed combined with oxaliplatin and control group treated with pemetrexed alone,55 cases in each group. The clinical effect and the incidences of adverse reactions were compared between two groups. Results The effect of study group was better than that of control group（ P 〈 0. 05）. There were no significant differences in the incidences of decreased hemoglobin,increased creatinine,vomiting,rash,allergic reactions between two groups（ P 〈 0. 05）. The incidences of leukopenia,thrombocytopenia,elevated AST,nausea,fatigue,feeling abnormal in the study group were higher than those in the control group（ P 〈 0. 05）. Conclusion The clinical effect of pemetrexed combined with oxaliplatin is superior to that of pemetrexed alone in the treatment of advanced NSCLC,but it should pay attention to controlling a lot of adverse reactions.